Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.

Solange Peters, MD, PhD, Chair, Medical Oncology, Lausanne University Hospital, Switzerland, discusses the ALEX study and the opportunities it presents for patients with ALK-positive non–small-cell…

David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.

Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.

David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.

Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.

Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.